Gallo S, et al. - In this 104-week, phase 3, randomized, double-blind study with a 26-week placebo-controlled period (Phase A) and a 78-week period (Phase B), researchers analyzed data to determine the long-term effectiveness and tolerability of ertugliflozin in patients with type 2 diabetes mellitus partially controlled on metformin. At week 52, 34.8% and 36.6% participants had HbA1c < 7.0%, and 24.6% and 33.7% at week 104, for 5- and 15-mg ertugliflozin. Treatment with ertugliflozin lowered fasting plasma glucose, body weight, and systolic blood pressure from baseline through week 104. A higher incidence of female genital mycotic infections with ertugliflozin and lower symptomatic hypoglycemia for ertugliflozin vs placebo/glimepiride were also recorded.